Year to date shares of Clearside Biomedical (CLSD) have risen by 50%, having pulled back after at one point doubling due to positive phase 3 data reported in March.
While Bay Area Biotech Investor gave me a heads up on it at the beginning of 2018, unfortunately I failed to follow through and investigate further.
Figure 1: CLSD daily advanced chart (Source: Finviz)
Wall Street brokerages predict that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will report earnings of ($0.20) per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from ($0.35) to ($0.08). Conatus Pharmaceuticals posted earnings of ($0.19) per share in the same quarter last year, which....More>>>
Trinity Biotech (NASDAQ: TRIB) is one of 25 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Trinity Biotech to related businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, profitability and institutional ownership.
Media stories about REGENXBIO (NASDAQ:RGNX) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. REGENXBIO....More>>>
Monday was a good start to the week for stocks, with major benchmarks climbing around half a percent on the day. Most market participants pointed to a lack of bad news over the weekend and anticipation about expected favorable economic data in the coming days as drivers of the generally positive attitude among investors.
But there are still plenty of factors that are preventing stocks overall....More>>>